Background
The NHK-Fintiv framework refers to a pair of PTAB precedential decisions — NHK Spring Co. v. Intri-Plex Technologies (2018) and Apple Inc. v. Fintiv, Inc. (2020) — that established the PTAB’s authority to deny IPR petitions based on the efficiency and fairness interests at stake when parallel district court litigation involving the same patent is already well-advanced. The framework directed the PTAB to consider six factors when deciding whether to exercise its discretion to deny institution under § 314(a), including: (1) whether a stay of district court proceedings pending IPR is likely; (2) the proximity of the district court trial date to the projected IPR final written decision; (3) investment in the parallel district court proceeding; (4) overlap between the IPR and district court issues; (5) whether the petitioner is a defendant in the district court case; and (6) other circumstances affecting the merits of discretionary denial.
The framework generated enormous controversy: patent holders argued it protected their patents from serial challenge; petitioners (primarily accused infringers) argued it allowed patent holders to avoid IPR review by racing to fast-moving district courts like the Western District of Texas, which had extremely fast trial schedules.
The PTAB’s Ruling
In Apple v. Fintiv, the PTAB formalized the six-factor analysis into a precedential standard for discretionary denial under § 314(a). The board held that when the district court trial date is imminent and there is substantial overlap between the IPR petition grounds and the invalidity defenses in district court, institutional efficiency concerns counsel in favor of denying IPR institution — particularly when the district court proceeding has substantially advanced and instituting IPR would result in duplicative proceedings with little benefit. The PTAB could weigh these factors holistically rather than requiring any single factor to be dispositive.
The Federal Circuit subsequently confirmed in multiple cases that Fintiv-based discretionary denials are generally not reviewable on appeal under Cuozzo/Thryv’s broad non-reviewability holding — further cementing the PTAB’s authority to manage its docket through discretionary denials.
Key Takeaways
- The PTAB has discretion under § 314(a) to deny IPR petitions based on the NHK-Fintiv six-factor analysis, even when the petition presents strong invalidity grounds — if the parallel district court proceeding is sufficiently advanced and the issues substantially overlap.
- Petitioners (accused infringers) should file IPR petitions promptly after service of a complaint and before the district court proceeding advances significantly — delay in filing creates Fintiv risk of discretionary denial.
- Patent holders can influence the IPR outcome by choosing to litigate in fast-moving district courts: filing in the Western District of Texas or other venues with aggressive trial schedules increases the risk that the PTAB will deny institution due to the imminent trial date.
- The NHK-Fintiv framework was eventually revised and limited by PTO Director guidance in 2022, responding to criticism that it had become a de facto barrier to IPR access, particularly in districts with very fast trial schedules.
Why It Matters
The NHK-Fintiv framework was one of the most consequential patent policy developments of the early 2020s. By giving the PTAB discretion to deny IPR based on the parallel litigation status, the framework shifted significant leverage to patent holders — enabling them to protect their patents from IPR challenge by ensuring their district court cases moved to trial before the PTAB could reach institution. Critics argued this effectively allowed patent assertion entities to select favorable venues and race to trial to avoid IPR review of their patents.
The framework generated intense debate that culminated in PTO Director guidance in 2022 substantially limiting Fintiv discretionary denials, particularly for cases in courts with trial dates more than a year away. The controversy over NHK-Fintiv also contributed to ongoing congressional and administrative debates about the proper role of IPR as a mechanism for patent quality review and the extent to which the PTAB should coordinate with or defer to district court proceedings in managing patent validity challenges.